Immutep Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease
SYDNEY, AUSTRALIA – 06 December 2022 – Immutep Limited (ASX: IMM;
NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage
biotechnology company developing novel LAG-3 immunotherapies for cancer
and autoimmune disease, announced today that a GMP compliant
manufacturing process has been established for IMP761, its proprietary
preclinical candidate for autoimmune diseases. The 200L scale attained
by Northway Biotech, an end-to-end biopharmaceutical contract
development and manufacturing organisation (CDMO), will ensure supply of
IMP761 for IND-enabling studies and ensuing clinical trials.
More info >> |
